ClinicalTrials.gg
CompletedNCT04167670Updated Apr 5, 2022Results posted

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection

A Phase 3 interventional study of Vonoprazan and Amoxicillin in Helicobacter Pylori Infection, sponsored by Phathom Pharmaceuticals, Inc.. Completed at 153 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-05.

Sponsored by Phathom Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,046
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To compare the efficacy of Helicobacter pylori (HP) eradication with vonoprazan dual and triple therapy regimens versus lansoprazole triple therapy regimen in participants with HP infection, excluding participants who had a clarithromycin or amoxicillin resistant strain of HP at baseline.

02

Conditions studied

  • Helicobacter Pylori Infection

Keywords

  • Vonoprazan
  • Lansoprazole
03

In context

Lead sponsor

Phathom Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; 2 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 11 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant is ≥ 18 years of age at the time of signing.
  2. In the opinion of the investigator or sub-investigators, the participant is capable of understanding and complying with protocol requirements.
  3. The participant signs and dates a written, informed consent form (ICF) and any required privacy authorization prior to the initiation of any study procedures. The participant is informed of the full nature and purpose of the study, including possible risks and side-effects. The participant has the ability to cooperate with the investigator. Ample time and opportunity should be given to read and understand verbal and/or written instructions.
  4. The participant has at least one of the following clinical conditions with confirmed HP+ infection demonstrated by a positive 13C-UBT during the Screening Period.

    • Dyspepsia (i.e. pain or discomfort centered in the upper abdomen) lasting at least 2 weeks
    • A confirmed diagnosis of functional dyspepsia
    • A recent / new diagnosis of (non-bleeding) peptic ulcer
    • A history of peptic ulcer not previously treated for HP infection
    • A requirement for long-term non-steroidal anti-inflammatory drug (NSAID) treatment at a stable dose of the NSAID
  5. A female participant of who is or may be routinely sexually active with a nonsterilized male partner agrees to routinely use adequate from the signing of informed consent until Day -2 and two forms of adequate contraception from Day -1 until 4 weeks after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. The participant has previously been treated with any regimen to attempt to eradicate HP.
  2. The participant has gastric or duodenal ulcer with endoscopic evidence of current or recent bleeding.
  3. The participant has confirmed diagnosis of gastric cancer by .
  4. The participant is receiving colchicine.
  5. The participant has received any compound (including those in post marketing studies) within 30 days prior to the start of the Screening Period. A participant who has screen failed from another clinical study and who has not been dosed may be considered for enrollment in this study.
  6. The participant is a study site employee, an immediate family member, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g., spouse, parent, child, sibling) or who may have consented under duress.
  7. The participant has cutaneous lupus erythematosus or systemic lupus erythematosus.
  8. The participant has had upper or lower gastrointestinal bleeding within 4 weeks prior to randomization.
  9. The participant has Zollinger-Ellison syndrome or other gastric acid hypersecretory conditions.
  10. The participant has a history of or allergies to vonoprazan (including the formulation : D-mannitol, microcrystalline cellulose, hydroxypropyl cellulose, fumaric acid, croscarmellose sodium, magnesium stearate, hypromellose, macrogol 8000, titanium oxide, red or yellow ferric oxide), PPIs, amoxicillin and/or clarithromycin, or any excipients used in the 13C-UBT: mannitol, citric acid or aspartame. Skin testing may be performed according to local standard practice to confirm hypersensitivity.
  11. The participant has a history of alcohol abuse, illegal drug use, or drug addiction within the 12 months prior to screening, or who regularly consume >21 units of alcohol (1 unit = 12 oz/300 mL beer, 1.5 oz/25 mL hard liquor/spirits, or 5 oz/100 mL wine) per week based on self-report. Participants must have a negative urine drug screen for cannabinoids/ tetrahydrocannabinol and non-prescribed medications at screening.
  12. The participant is taking any excluded medications or treatments listed in the protocol.
  13. If female, the participant is pregnant, lactating, or intending to become pregnant before, during, or within 4 weeks after participating in this study; or intending to donate ova during such time period.
  14. The participant has a history or clinical manifestations of significant central nervous system, cardiovascular, pulmonary, hepatic, renal, metabolic, other gastrointestinal, urological, endocrine or hematological disease that, in the opinion of the investigator, would confound the study results or compromise participants safety.
  15. The participant requires hospitalization or has surgery scheduled during the course of the study or has undergone major surgical procedures within 30 days prior to the Screening Visit.
  16. The participant has a history of (including MALToma) or has been treated for malignancy within 5 years prior to the start of the Screening Period (Visit 1) (the participant may be included in the study if he/she has cured cutaneous basal cell carcinoma or cervical carcinoma in situ).
  17. The participant has acquired immunodeficiency syndrome or infection, or tests positive for the surface antigen, virus (HCV) antibody or HCV RNA. However, participants who test positive for HCV antibody, but negative for HCV RNA are permitted to participate.
  18. The participant has any of the following abnormal laboratory test values at the start of the Screening Period:

    1. Creatinine levels: >2 mg/dL (>177 μmol/L).
    2. (ALT) or aspartate aminotransferase (AST) >2 × the (ULN) or total >2 × ULN.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,046 participants (actual)

Study arms

  • Experimental
    Vonoprazan dual therapy

    Participants will receive vonoprazan 20 mg twice daily (BID) in conjunction with amoxicillin 1 g, three times daily, for 14 days.

    Drug: Vonoprazan · Drug: Amoxicillin

  • Experimental
    Vonoprazan triple therapy

    Participants will receive vonoprazan 20 mg twice daily (BID) in conjunction with amoxicillin 1 g BID and clarithromycin 500 mg, BID, for 14 days.

    Drug: Vonoprazan · Drug: Amoxicillin · Drug: Clarithromycin

  • Active comparator
    Lansoprazole triple therapy

    Participants will receive lansoprazole 30 mg twice daily (BID) in conjunction with amoxicillin 1 g BID and clarithromycin 500 mg BID, for 14 days.

    Drug: Amoxicillin · Drug: Clarithromycin · Drug: Lansoprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Successful Helicobacter Pylori (H Pylori) Eradication in Participants Without a Clarithromycin- or Amoxicillin-resistant Strain of H Pylori at Baseline

    H pylori eradication was determined by the \^13C-UBT test.

    Time frame: Baseline to 4 weeks after the last dose of study drugs (maximum duration of treatment was 2 weeks)

Secondary outcomes

  1. Percentage of Participants With Successful Helicobacter Pylori (H Pylori) Eradication in Participants With a Clarithromycin-resistant Strain of H Pylori at Baseline

    H pylori eradication was determined by the \^13C-UBT test.

    Time frame: Baseline to 4 weeks after the last dose of study drugs (maximum duration of treatment was 2 weeks)

  2. Percentage of All Participants With Successful Helicobacter Pylori (H Pylori) Eradication

    H pylori eradication was determined by the \^13C-UBT test.

    Time frame: Baseline to 4 weeks after the last dose of study drugs (maximum duration of treatment was 2 weeks)

07

Results

Posted Apr 5, 2022

Participant flow

1046 participants were randomized at 103 study sites, including 71 in the United States and 32 in Europe.

Participant flow — Overall Study
MilestoneVonoprazan Dual TherapyVonoprazan Triple TherapyLansoprazole Triple Therapy
Started349349348
Received study drugs348346345
Completed334331334
Not completed151814
Withdrew: Pretreatment event, adverse event, or serious adverse event174
Withdrew: Significant protocol deviation310
Withdrew: Lost to follow-up033
Withdrew: Voluntary withdrawal011
Withdrew: Withdrawal of consent413
Withdrew: Miscellaneous753

Outcome measures

PrimaryPercentage of Participants With Successful Helicobacter Pylori (H Pylori) Eradication in Participants Without a Clarithromycin- or Amoxicillin-resistant Strain of H Pylori at Baseline

H pylori eradication was determined by the \^13C-UBT test.

Time frame:
Baseline to 4 weeks after the last dose of study drugs (maximum duration of treatment was 2 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Successful Helicobacter Pylori (H Pylori) Eradication in Participants Without a Clarithromycin- or Amoxicillin-resistant Strain of H Pylori at Baseline
percentage of participantsVonoprazan Dual TherapyVonoprazan Triple TherapyLansoprazole Triple Therapy
Percentage of Participants With Successful Helicobacter Pylori (H Pylori) Eradication in Participants Without a Clarithromycin- or Amoxicillin-resistant Strain of H Pylori at Baseline78.584.778.8
Statistical analysis
  • Vonoprazan Dual Therapy vs Lansoprazole Triple Therapy · Farrington and Manning test · p = 0.0037 · Percentage difference: -0.3 · 95% CI -7.39 to 6.76The confidence interval of the difference in H pylori eradication rates between vonoprazan dual therapy and lansoprazole triple therapy was calculated via the Miettinen and Nurminen method.
  • Vonoprazan Triple Therapy vs Lansoprazole Triple Therapy · Farrington and Manning test · p = <0.0001 · Percentage difference: 5.9 · 95% CI -0.75 to 12.62The confidence interval of the difference in H pylori eradication rates between vonoprazan triple therapy and lansoprazole triple therapy was calculated via the Miettinen and Nurminen method.
SecondaryPercentage of Participants With Successful Helicobacter Pylori (H Pylori) Eradication in Participants With a Clarithromycin-resistant Strain of H Pylori at Baseline

H pylori eradication was determined by the \^13C-UBT test.

Time frame:
Baseline to 4 weeks after the last dose of study drugs (maximum duration of treatment was 2 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Successful Helicobacter Pylori (H Pylori) Eradication in Participants With a Clarithromycin-resistant Strain of H Pylori at Baseline
percentage of participantsVonoprazan Dual TherapyVonoprazan Triple TherapyLansoprazole Triple Therapy
Percentage of Participants With Successful Helicobacter Pylori (H Pylori) Eradication in Participants With a Clarithromycin-resistant Strain of H Pylori at Baseline69.665.831.9
Statistical analysis
  • Vonoprazan Dual Therapy vs Lansoprazole Triple Therapy · Farrington and Manning test · p = <0.0001 · Percentage difference: 37.7 · 95% CI 20.54 to 52.56The confidence interval of the difference in H pylori eradication rates between vonoprazan dual therapy and lansoprazole triple therapy was calculated via the Miettinen and Nurminen method.
  • Vonoprazan Triple Therapy vs Lansoprazole Triple Therapy · Farrington and Manning test · p = <0.0001 · Percentage difference: 33.8 · 95% CI 17.74 to 48.12The confidence interval of the difference in H pylori eradication rates between vonoprazan triple therapy and lansoprazole triple therapy was calculated via the Miettinen and Nurminen method.
SecondaryPercentage of All Participants With Successful Helicobacter Pylori (H Pylori) Eradication

H pylori eradication was determined by the \^13C-UBT test.

Time frame:
Baseline to 4 weeks after the last dose of study drugs (maximum duration of treatment was 2 weeks)
Reported as:
Number · percentage of participants
Percentage of All Participants With Successful Helicobacter Pylori (H Pylori) Eradication
percentage of participantsVonoprazan Dual TherapyVonoprazan Triple TherapyLansoprazole Triple Therapy
Percentage of All Participants With Successful Helicobacter Pylori (H Pylori) Eradication77.280.868.5
Statistical analysis
  • Vonoprazan Dual Therapy vs Lansoprazole Triple Therapy · Farrington and Manning test · p = 0.0063 · Percentage difference: 8.7 · 95% CI 1.86 to 15.44The confidence interval of the difference in H pylori eradication rates between vonoprazan dual therapy and lansoprazole triple therapy was calculated via the Miettinen and Nurminen method.
  • Vonoprazan Triple Therapy vs Lansoprazole Triple Therapy · Farrington and Manning test · p = 0.0001 · Percentage difference: 12.3 · 95% CI 5.72 to 18.81

Adverse events

Collected over Baseline to 4 weeks after the last dose of study drugs (maximum duration of treatment was 2 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vonoprazan Dual Therapy0/348 (0%)5/348 (1.4%)20/348 (5.7%)
Vonoprazan Triple Therapy2/346 (0.6%)6/346 (1.7%)27/346 (7.8%)
Lansoprazole Triple Therapy1/345 (0.3%)3/345 (0.9%)48/345 (13.9%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventVonoprazan Dual TherapyVonoprazan Triple TherapyLansoprazole Triple Therapy
Pneumonia viralInfections and infestations0/3480/3461/345
Cholecystitis acuteHepatobiliary disorders0/3480/3461/345
Peripheral ischaemiaVascular disorders0/3480/3461/345
Cardiac arrestCardiac disorders0/3481/3460/345
Coronary artery occlusionCardiac disorders0/3481/3460/345
Corona virus infectionInfections and infestations1/3481/3460/345
Duodenal polypGastrointestinal disorders0/3481/3460/345
Jaw fractureInjury, poisoning and procedural complications0/3481/3460/345
Spinal painMusculoskeletal and connective tissue disorders0/3481/3460/345
Atrial fibrillationCardiac disorders1/3480/3460/345
Most frequent other events
Most frequent other events
EventVonoprazan Dual TherapyVonoprazan Triple TherapyLansoprazole Triple Therapy
DiarrhoeaGastrointestinal disorders18/34814/34633/345
DysgeusiaNervous system disorders2/34815/34621/345

Baseline characteristics

Randomized Set - All participants randomly assigned to receive study drug regardless of whether or not they received a dose of study drug during the study.

Age, Continuous
Age, Continuous(years)Vonoprazan Dual TherapyVonoprazan Triple TherapyLansoprazole Triple TherapyTotal
Mean51.9 ± 13.4750.7 ± 13.8851.6 ± 13.6151.4 ± 13.65
Sex: Female, Male
Sex: Female, Male(Participants)Vonoprazan Dual TherapyVonoprazan Triple TherapyLansoprazole Triple TherapyTotal
Female210226216652
Male139123132394
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Vonoprazan Dual TherapyVonoprazan Triple TherapyLansoprazole Triple TherapyTotal
Hispanic or Latino959989283
Not Hispanic or Latino251249259759
Unknown or Not Reported3104
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vonoprazan Dual TherapyVonoprazan Triple TherapyLansoprazole Triple TherapyTotal
White316307312935
Black or African-American22302577
Asian46616
American Indian or Alaska Native0112
Native Hawaiian or Other Pacific Islander1001
Other4138
Unknown1113
Not Reported1304
08

Study locations

153 sites
  • Pinnacle Research Group
    Anniston, Alabama 36207, United States
  • North Alabama Research Center, LLC
    Athens, Alabama 35611, United States
  • Synexus Clinical Research US, Inc. - Alabama
    Birmingham, Alabama 35211, United States
  • Medical Affiliated Research Center Inc
    Huntsville, Alabama 35801, United States
  • Synexus Clinical Research US, Inc. - East Valley Family Physicians, PLC
    Chandler, Arizona 85224, United States
  • Synexus Clinical Research US, Inc. - Central Arizona Medical Associates, PC
    Mesa, Arizona 85206, United States
  • Synexus Clinical Research US, Inc. - Desert Clinical Research, LLC
    Mesa, Arizona 85213, United States
  • Elite Clinical Studies - Phoenix - BTC - PPDS
    Phoenix, Arizona 85018, United States
  • Hope Research Institute LLC
    Phoenix, Arizona 85018, United States
  • Del Sol Research Management - BTC - PPDS
    Tucson, Arizona 85712, United States
  • Preferred Research Partners - ClinEdge - PPDS
    Little Rock, Arkansas 72211, United States
  • Applied Research Center of Little Rock
    Little Rock, Arkansas 72212, United States
  • Arkansas Gastroenterology
    North Little Rock, Arkansas 72117, United States
  • Atria Clinical Research - BTC - PPDS
    North Little Rock, Arkansas 72117, United States
  • Anaheim Clinical Trials LLC
    Anaheim, California 92801, United States
  • GW Research, Inc. - ClinEdge - PPDS
    Chula Vista, California 91910, United States
  • eStudySite - Chula Vista - PPDS
    Chula Vista, California 91911, United States
  • Kindred Medical Institute for Clinical Trials, LLC
    Corona, California 92879, United States
  • HB Clinical Trials, Inc.
    Fountain Valley, California 92708-7510, United States
  • OM Research LLC - Lancaster - ClinEdge - PPDS
    Lancaster, California 93534, United States
  • Torrance Clinical Research Institute
    Lomita, California 90717, United States
  • Southern California Research Institute Medical Group, Inc.
    Los Angeles, California 90045, United States
  • Facey Medical Foundation
    Mission Hills, California 91345, United States
  • Palmtree Clinical Research
    Palm Springs, California 92262, United States
  • Precision Research Institute
    San Diego, California 92114, United States
  • Medical Associates Research Group, Inc.
    San Diego, California 92123, United States
  • Paragon Rx Clinical, Inc.
    Santa Ana, California 92703, United States
  • Synexus Clinical Research US, Inc.
    Colorado Springs, Colorado 80909, United States
  • Western States Clinical Research, Inc.
    Wheat Ridge, Colorado 80033, United States
  • Gastroenterology Associates of Fairfield County
    Bridgeport, Connecticut 06606, United States
  • Connecticut Clinical Research Foundation
    Bristol, Connecticut 06010, United States
  • Riverside Clinical Research
    Edgewater, Florida 32132, United States
  • Research Centers of America - ERG
    Hollywood, Florida 33024, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • ENCORE Borland-Groover Clinical Research - ERN - PPDS
    Jacksonville, Florida 32256, United States
  • Columbus Clinical Services LLC
    Miami, Florida 33125, United States
  • Jesscan Medical Research
    Miami, Florida 33134, United States
  • Nuren Medical and Research Center
    Miami, Florida 33144, United States
  • Premier Research Associate-Miami
    Miami, Florida 33165, United States
  • G. Medical Center
    Orlando, Florida 32807, United States
  • Advanced Gastroenterology Associates, LLC
    Palm Harbor, Florida 34684, United States
  • Innovation Medical Research Center
    Palmetto Bay, Florida 33157, United States
  • Synexus Clinical Research US, Inc. - St. Petersburg
    Pinellas Park, Florida 33781, United States
  • Precision Clinical Research, LLC
    Sunrise, Florida 33351, United States
  • Guardian Angel Research Center
    Tampa, Florida 33614, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 30342, United States
  • Nexgen Research Center
    Atlanta, Georgia 30345, United States
  • Gastroenterology Associates of Central Georgia, LLC
    Macon, Georgia 31201, United States
  • In Quest Medical Research - ClinEdge - PPDS
    Peachtree Corners, Georgia 30071, United States
  • IL Gastroenterology Group
    Gurnee, Illinois 60031, United States
  • Summit Digestive & Liver Disease Specialists
    Oakbrook Terrace, Illinois 60181, United States
  • Gastroenterology Health Partners, PLLC
    New Albany, Indiana 47150, United States
  • Iowa Digestive Disease Center
    Clive, Iowa 50325, United States
  • Clinical Trials Management LLC
    Covington, Louisiana 70433, United States
  • CroNOLA, LLC.
    Houma, Louisiana 70360, United States
  • Clinical Trials Management LLC
    Metairie, Louisiana 70006, United States
  • Meridian Clinical Research-(Rockville Maryland)
    Rockville, Maryland 20854, United States
  • Clinical Associates
    Towson, Maryland 21286, United States
  • Oakland Medical Research Center
    Troy, Michigan 48085, United States
  • The Alliance for Multispecialty Research, LLC
    Kansas City, Missouri 64114, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Heartland Clinical Research, Inc
    Omaha, Nebraska 68134, United States
  • Synexus Clinical Research US, Inc. - Site 1
    Henderson, Nevada 89052, United States
  • Synexus Clinical Research US, Inc. - Site 2
    Henderson, Nevada 89052, United States
  • Sierra Clinical Research - ClinEdge - PPDS
    Las Vegas, Nevada 89106, United States
  • Office - Site 1
    Las Vegas, Nevada 89119, United States
  • Office - Site 2
    Las Vegas, Nevada 89128, United States
  • Advanced Research Institute
    Reno, Nevada 89511, United States
  • Drug Trials America - ClinEdge
    Hartsdale, New York 10530, United States
  • Carolinas Research Center
    Charlotte, North Carolina 28215, United States
  • Duke University Medical Center
    Durham, North Carolina 27710-4000, United States
  • Medication Management LLC
    Greensboro, North Carolina 27408, United States
  • Carolina Research
    Greenville, North Carolina 27834, United States
  • Peters Medical Research, LLC - ClinEdge - PPDS
    High Point, North Carolina 27262, United States
  • Dayton Gastroenterology, Inc
    Dayton, Ohio 45415, United States
  • Prestige Clinical Research
    Franklin, Ohio 45005, United States
  • Central Sooner Research
    Norman, Oklahoma 73071, United States
  • Synexus Clinical Research US, Inc. - Anderson
    Anderson, South Carolina 29621, United States
  • Clinical Trials of South Carolina
    Charleston, South Carolina 29406, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Rapid City Medical Center LLP
    Rapid City, South Dakota 57701, United States
  • Multi Specialty Clinical Research
    Johnson City, Tennessee 37601, United States
  • Clinical Research Associates Inc
    Nashville, Tennessee 37203, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212, United States
  • Inquest Clinical Research
    Baytown, Texas 77521, United States
  • Synexus Clinical Research US, Inc. - Dallas
    Dallas, Texas 75234, United States
  • Texas Tech University Health Sciences Center El Paso
    El Paso, Texas 79905, United States
  • Ben Taub General Hospital
    Houston, Texas 77030, United States
  • Precision Research Institute, LLC
    Houston, Texas 77036, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77084, United States
  • Rio Grande Gastroenterology
    McAllen, Texas 78503, United States
  • Digestive System Healthcare
    Pasadena, Texas 77505, United States
  • Pearland Physicians
    Pearland, Texas 77581, United States
  • Synexus Clinical Research US, Inc. - Plano
    Plano, Texas 75093, United States
  • Quality Research Inc
    San Antonio, Texas 78209, United States
  • Gastroenterology Research of San Antonio (GERSA)
    San Antonio, Texas 78229, United States
  • San Antonio Gastroenterology Associates Clinical Trials (SAGACT PLLC)
    San Antonio, Texas 78229, United States
  • Southern Star Research Institute, LLC
    San Antonio, Texas 78229, United States
  • Synexus Clinical Research US, Inc. - Layton
    Layton, Utah 84041, United States
  • Advanced Research Institute
    Ogden, Utah 84405, United States

Showing the first 100 of 153 sites across 6 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Megraud F, Graham DY, Howden CW, Trevino E, Weissfeld A, Hunt B, Smith N, Leifke E, Chey WD. Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe. Am J Gastroenterol. 2023 Feb 1;118(2):269-275. doi: 10.14309/ajg.0000000000002045. Epub 2022 Sep 30. PubMed 36191284 ↗
  • Chey WD, Megraud F, Laine L, Lopez LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology. 2022 Sep;163(3):608-619. doi: 10.1053/j.gastro.2022.05.055. Epub 2022 Jun 6. PubMed 35679950 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Mar 2021, 15 months.

Results were first posted in Apr 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2019
First posted
Nov 19, 2019
StartActual
Dec 10, 2019
Primary completionActual
Mar 10, 2021
CompletionActual
Mar 18, 2021
Results first posted
Apr 5, 2022
Last update
Apr 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04167670
Lead sponsor
Phathom Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Nov 19, 2019
Start date
Dec 10, 2019
Primary completion
Mar 10, 2021
Completion
Mar 18, 2021
Results posted
Apr 5, 2022
Last update
Apr 5, 2022

Study contacts

Medical Director
study director · Phathom Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vonoprazan · Clarithromycin

Start the discussion